Cargando…
DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma
Recently discovered DNAJB1-PRKACA oncogenic fusions have been considered diagnostic for fibrolamellar hepatocellular carcinoma. In this study, we describe six pancreatobiliary neoplasms with PRKACA fusions, five of which harbor the DNAJB1-PRKACA fusion. All neoplasms were subjected to a hybridizatio...
Autores principales: | Vyas, Monika, Hechtman, Jaclyn F., Zhang, Yanming, Benayed, Ryma, Yavas, Aslihan, Askan, Gokce, Shia, Jinru, Klimstra, David S., Basturk, Olca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125037/ https://www.ncbi.nlm.nih.gov/pubmed/31676785 http://dx.doi.org/10.1038/s41379-019-0398-2 |
Ejemplares similares
-
Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA
por: Neumayer, Christoph, et al.
Publicado: (2023) -
Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma
por: Tomasini, Michael D., et al.
Publicado: (2018) -
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
por: Bauer, Jens, et al.
Publicado: (2022) -
Mesenchymal Tumors Involving the Pancreas: A Clinicopathologic Analysis and Review of the Literature
por: Askan, Gokce, et al.
Publicado: (2022) -
Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
por: Askan, Gokce, et al.
Publicado: (2021)